Joseph Sala - 13 Mar 2026 Form 4 Insider Report for EXPONENT INC (EXPO)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
16 Mar 2026, 16:21:34 UTC
Prior SEC filing
13 Mar 2026
Next SEC filing
13 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
By: Wendy Whitehouse For: Joseph Sala

Key filing fact

Joseph Sala filed Form 4 for EXPONENT INC (EXPO) on 16 Mar 2026.

Key facts

  • This page summarizes Joseph Sala's Form 4 filing for EXPONENT INC (EXPO).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 16 Mar 2026, 16:21.

Change

  • Previous filing in this sequence was filed on 13 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002046938 Primary reporting owner

Sala Joseph

Relationship
Group Vice President
Address
149 COMMONWEALTH DRIVE, MENLO PARK
Signature
By: Wendy Whitehouse For: Joseph Sala
Signature date
16 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EXPO transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares
+9,798
Change %
Price
Shares after
9,798
Date
13 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
9,798
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

1-for-1.

Footnote F2

Not applicable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .